Specialist in Psychiatric and Neurological Disorders!
The start of the year with a revenue increase of 18% and EPS growth of 15% was strong. The subsequent raising of the forecast could enable rising stock prices!
The anticipated uncertainty in the U.S. business may be exaggerated!
Reading Time: 1 minute
H. Lundbeck A/S Ordinary Shares B (A3DMBV) (i.) is a healthcare company focused on medications for the treatment of depression, schizophrenia, Alzheimer's, Parkinson's, migraines, and epilepsy. I believe the company is addressing several diseases where the demand for treatment could increase in the future, partly due to an aging population. On May 14, the company already attracted positive attention. Expectations for revenue and EPS were exceeded in the first quarter. Particularly positive was the demand for Vyepti for migraine prevention, which...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
